Today’s cardiometabolic care is moving beyond a singular focus on LDL cholesterol toward a more comprehensive therapeutic strategy. Properly formulated and prescribed, niacin merits renewed consideration as an evidence-based nutritional intervention that favorably impacts multiple lipid parameters associated with atherosclerotic CVD.
A systematic review found that extended-release wax-matrix niacin improved several blood lipid measures, while also highlighting the need to monitor fasting blood glucose.
A six-week randomized, double-blind, placebo-controlled trial compared 1,500 mg/day of wax-matrix extended-release niacin with the same dose of inositol hexanicotinate, often marketed as “no-flush” niacin. Wax-matrix niacin significantly reduced total cholesterol, LDL cholesterol, and non-HDL cholesterol while increasing HDL cholesterol. Inositol hexanicotinate produced no significant lipid improvements compared with placebo. A small pharmacokinetic substudy also found evidence of niacin absorption with the wax-matrix formulation but no meaningful bioavailability with inositol hexanicotinate.
Nicotinic acid has a distinctive role in nutritional lipid support. By influencing free-fatty-acid release, hepatic triglyceride production, and VLDL synthesis, niacin works upstream in lipid metabolism. Published clinical research has also examined its effects on lipoprotein(a), an important largely inherited cardiovascular biomarker. This article explores niacin’s mechanisms, its relationship with NAD+, and how extended-release delivery may help address flushing and improve long-term adherence.
For decades, clinicians have focused on which nutrients to recommend and at what dose. But a growing body of research suggests another variable may be just as important: how those nutrients are delivered to the body over time. Most supplements on the market—whether powders, capsules, liquids, or standard tablets—release theirRead
One of the reasons Endur-Acin® ER has maintained a loyal following among practitioners for decades is that its clinical research has consistently demonstrated unusually low flushing-related discontinuation rates. Results from multiple clinical trials indicate that Endur-Acin® ER is associated with dropout rates of about 4–5% on average from minor sideRead
Patients often stop taking supplements not because they reject the protocol, but because the regimen creates too much friction. Learn how practitioners can improve adherence through simpler dosing, predictable delivery, patient education, and early follow-up.
In clinical practice, practitioners often see patients with stress-related issues due to lifestyle, environment, and other common stressors. This frequently overlaps with occasional sleep issues, trouble focusing, and heightened reactivity. While many interventions exist, L-theanine—an amino acid naturally found in green tea—has demonstrated a unique ability to promote relaxation withoutRead
Patients who experience occasional stress from lifestyle factors often present with occasional episodes of mental overstimulation, difficulty relaxing, and trouble staying asleep. As interest in non-pharmacologic options continues to grow, nutraceuticals such as GABA and L-theanine are frequently considered for their ability to promote relaxation and help manage stress. WhileRead
Sleep disturbances are one of the most common complaints in clinical practice, often reflecting imbalances in neurotransmitters and stress physiology. Beyond simple sleep quantity, the quality and structure of sleep—particularly the balance of initiation, deep stages, and REM—determine how restorative it is. Two natural bioactive compounds, 5-HTP and L-theanine, offerRead
